

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM435735

<b>SUBMISSION TYPE:</b>	RESUBMISSION
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST
<b>RESUBMIT DOCUMENT ID:</b>	900410281
<b>SEQUENCE:</b>	3

## CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Hudson Bay Master Fund Ltd. as successor-in-interest by assignment to Redpath Equity Representative, LLC		06/08/2017	Corporation: DELAWARE

## RECEIVING PARTY DATA

<b>Name:</b>	PDI, Inc. n/k/a Interpace Diagnostics Group, Inc.
<b>Street Address:</b>	300 Interpace Parkway
<b>Internal Address:</b>	Morris Corporate Center 1, Building A
<b>City:</b>	Parsippany
<b>State/Country:</b>	NEW JERSEY
<b>Postal Code:</b>	07054
<b>Entity Type:</b>	Corporation: DELAWARE
<b>Name:</b>	Group DCA, LLC
<b>Street Address:</b>	300 Interpace Parkway
<b>Internal Address:</b>	Morris Corporate Center 1, Building A
<b>City:</b>	Parsippany
<b>State/Country:</b>	NEW JERSEY
<b>Postal Code:</b>	07054
<b>Entity Type:</b>	Limited Liability Company: DELAWARE
<b>Name:</b>	Interpace Biopharma, LLC
<b>Street Address:</b>	300 Interpace Parkway
<b>Internal Address:</b>	Morris Corporate Center 1, Building A
<b>City:</b>	Parsippany
<b>State/Country:</b>	NEW JERSEY
<b>Postal Code:</b>	07054
<b>Entity Type:</b>	Limited Liability Company: DELAWARE
<b>Name:</b>	Interpace Diagnostics, LLC
<b>Street Address:</b>	300 Interpace Parkway
<b>Internal Address:</b>	Morris Corporate Center 1, Building A

TRADEMARK

<b>City:</b>	Parsippany
<b>State/Country:</b>	NEW JERSEY
<b>Postal Code:</b>	07054
<b>Entity Type:</b>	Limited Liability Company: DELAWARE
<b>Name:</b>	Interpace Diagnostics Lab, Inc. f/k/a JS Genetics, Inc.
<b>Street Address:</b>	300 Interpace Parkway
<b>Internal Address:</b>	Morris Corporate Center 1, Building A
<b>City:</b>	Parsippany
<b>State/Country:</b>	NEW JERSEY
<b>Postal Code:</b>	07054
<b>Entity Type:</b>	Corporation: DELAWARE
<b>Name:</b>	Redpath Acquisition Sub, Inc. n/k/a Interpace Diagnostics Corporation, its successor-in-interest by merger
<b>Street Address:</b>	300 Interpace Parkway
<b>Internal Address:</b>	Morris Corporate Center 1, Building A
<b>City:</b>	Parsippany
<b>State/Country:</b>	NEW JERSEY
<b>Postal Code:</b>	07054
<b>Entity Type:</b>	Corporation: DELAWARE

**PROPERTY NUMBERS Total: 17**

<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>
<b>Registration Number:</b>	3208314	PATHFINDERTG
<b>Registration Number:</b>	4071426	MIRINFORM
<b>Registration Number:</b>	4593300	PD ONE
<b>Registration Number:</b>	4593299	PD ONE
<b>Registration Number:</b>	4071427	MIRINFORM
<b>Registration Number:</b>	5142307	BARREGEN
<b>Serial Number:</b>	86910938	BARREGEN ESOPHAGEAL CANCER RISK CLASSIFI
<b>Registration Number:</b>	5072603	INTERPACE DIAGNOSTICS
<b>Registration Number:</b>	4646544	INTERPACE DIAGNOSTICS
<b>Registration Number:</b>	4882368	
<b>Registration Number:</b>	5067909	
<b>Registration Number:</b>	4796668	PANCRAGEN
<b>Serial Number:</b>	86357914	PANCRAMIR
<b>Serial Number:</b>	87178397	PANDNA
<b>Registration Number:</b>	4729240	POWER IN PERFORMANCE
<b>Registration Number:</b>	4729279	THYGENX
<b>Registration Number:</b>	4882519	THYRAMIR

**CORRESPONDENCE DATA****Fax Number:** 2159814750*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.***Phone:** 2159814194**Email:** kennedyp@pepperlaw.com, catalant@pepperlaw.com**Correspondent Name:** Paul J. Kennedy**Address Line 1:** 3000 Two Logan Square**Address Line 2:** Eighteenth and Arch Streets**Address Line 4:** Philadelphia, PENNSYLVANIA 19103-2799

<b>ATTORNEY DOCKET NUMBER:</b>	130654.44
<b>NAME OF SUBMITTER:</b>	Paul J. Kennedy
<b>SIGNATURE:</b>	/Paul J. Kennedy/
<b>DATE SIGNED:</b>	07/19/2017

**Total Attachments: 14**

source=Security Interest #3#page1.tif  
source=Security Interest #3#page2.tif  
source=Security Interest #3#page3.tif  
source=Security Interest #3#page4.tif  
source=Security Interest #3#page5.tif  
source=Security Interest #3#page6.tif  
source=Security Interest #3#page7.tif  
source=Security Interest #3#page8.tif  
source=Security Interest #3#page9.tif  
source=Security Interest #3#page10.tif  
source=Security Interest #3#page11.tif  
source=Security Interest #3#page12.tif  
source=Security Interest #3#page13.tif  
source=Security Interest #3#page14.tif

**TERMINATION AND RELEASE OF SECURITY INTEREST  
IN INTELLECTUAL PROPERTY  
(TRADEMARKS AND PATENTS)**

This Termination and Release of Security Interest in Intellectual Property (this “Release”) is made this 8th day of June, 2017, by Hudson Bay Master Fund Ltd (“Secured Party”), in favor of PDI, Inc. (n/k/a Interpace Diagnostics Group, Inc.), a Delaware corporation (“IDG”), Group DCA, LLC, a Delaware limited liability company, Interpace Biopharma, LLC, a Delaware limited liability company, Interpace Diagnostics, LLC, a Delaware limited liability company (“ID LLC”), Interpace Diagnostics Lab, Inc. (f/k/a JS Genetics, Inc.), a Delaware corporation and Redpath Acquisition Sub, Inc. (n/k/a Interpace Diagnostics Corporation, its successor-in-interest by merger), a Delaware corporation (“IDC”) (collectively, the “Grantors”).

WHEREAS, pursuant to the terms and conditions of that Guarantee and Collateral Agreement by Grantor in favor of REDPATH EQUITYHOLDER REPRESENTATIVE, LLC (“Redpath”), dated as of October 31, 2014 (the “GCA”), Grantors granted to Redpath a continuing security interest in all of Grantors’ right, title and interest in, to and under the Collateral, including but not limited to, the Intellectual Property (capitalized terms not otherwise defined herein shall have the meanings given to them in the GCA);

WHEREAS, Grantors entered into the GCA in favor of Redpath pursuant to the terms and conditions of the Loan Documents, including but not limited to, that certain Non-Negotiable Subordinated Secured Promissory Note dated October 31, 2014 issued by IDG and ID, LLC, as borrowers, to Redpath;

WHEREAS, the GCA was recorded with the United States Patent and Trademark Office (“USPTO”) on September 23, 2016 at Reel/Frame 005883/0319 with respect to trademark collateral;

WHEREAS, the GCA was recorded with the USPTO on September 23, 2016 at Reel/Frame 040125/0251 with respect to patent collateral;

WHEREAS, the security interests in the assets of the Grantors under the GCA, among other things, were assigned by Redpath to Secured Party pursuant to that certain Securities Purchase Agreement, dated as of March 22, 2017, by and between Redpath and Secured Party and, accordingly, IDG, IDC and ID LLC entered into that certain Amended and Restated Intellectual Property Security Agreement, dated as of March 23, 2017, in favor of the Secured Party (the “Amended and Restated Security Agreement”);

WHEREAS, the Grantors’ obligations under the GCA and the Amended and Restated Security Agreement have been satisfied in full and the security interest granted to Secured Party, as successor-in-interest to Redpath, has been released by Secured Party;

WHEREAS, Secured Party has the requisite power and authority to release and discharge its security interest in and to the Intellectual Property; and

WHEREAS, the parties desire to confirm and evidence the termination and release of the security interest in, to and under the Intellectual Property.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Secured Party, on behalf of itself and its successors, legal representatives and assigns, hereby unconditionally, irrevocably and absolutely (i) assigns to Grantors all of Secured Party's right, title and interest (if any) in and to the Intellectual Property and (ii) terminates, cancels, releases and forever discharges any and all security interests it holds in, to and under the Intellectual Property, including, without limitation, the trademarks and patents set forth on Exhibit A and Exhibit B, respectively.

Secured Party shall take all further reasonable actions, and provide to Grantors or their successors, assigns or other legal representatives, all such reasonable cooperation and assistance (including, without limitation, the execution and delivery of any and all documents or other instruments), requested by Grantors to more fully and effectively effectuate the purposes of this Release, in each case, at Grantors' expense. By this instrument, Secured Party authorizes and requests Grantors to record this Release with the USPTO.

This Release shall be governed by the internal laws of the State of New York, without giving effect to the choice of law provisions thereof.

SIGNATURE PAGE FOLLOWS

IN WITNESS WHEREOF, Investor has caused this Release to be executed by its respective duly authorized representative as of the date first above written.

**HUDSON BAY MASTER FUND LTD**, as  
successor-in-interest by assignment to Redpath  
Equityholder Representative, LLC

By:   
Name: George Antonopoulos  
Title: Authorized Signatory

**Exhibit A  
Trademarks**

<u>Grantor</u>	<u>Country</u>	<u>Trademark</u>	<u>Application or Registration No.</u>	<u>Filing Date</u>	<u>Registration Date</u>	<u>Assignees</u>
Interpace Diagnostics Corporation	US	PATHFINDERTG	3208314	3/28/2006	2/13/2007	SWK Funding, LLC
Interpace Diagnostics, LLC	US	MIRINFORM	4071426	6/21/2010	12/13/2011	Redpath Equity Holder Representative
Publicis Healthcare Solutions, Inc.	US	PD ONE and Design	4593300	3/12/2012	8/26/2014	Publicis Healthcare Solutions, Inc.
Publicis Healthcare Solutions, Inc.	US	PD ONE	4593299	3/12/2012	8/26/2014	Publicis Healthcare Solutions, Inc.
Interpace Diagnostics, LLC	US	MIRINFORM	4071427	6/21/2010	12/13/2011	Redpath Equity Holder Representative
Interpace Diagnostics, LLC	WIPO	MIRINFORM	1162299	5/8/2013	5/8/2013	N/A
Interpace Diagnostics, LLC	WIPO	MIRINFORM	1162175	5/8/2013	5/8/2013	N/A
Interpace Diagnostics, LLC	US	BarreGen	5142307	2/5/15	2/14/17	N/A
Interpace Diagnostics, LLC	US	BARREGEN ESOPHAGEAL CANCER RISK CLASSIFIER	86/910938	2/17/16	N/A	N/A
Interpace Diagnostics, LLC	US	Interpace Diagnostics	5072603	3/17/16	11/1/16	N/A
Interpace Diagnostics, LLC	US	INTERPACE DIAGNOSTICS in Class 35	4646544	11/27/13	11/25/14	SWK Funding LLC, as Agent Redpath Equity Holder Representative
Interpace Diagnostics, LLC	US	MOLECULE LOGO	4882368	5/23/14	1/5/16	SWK Funding LLC, as Agent Redpath Equity Holder Representative

<u>Grantor</u>	<u>Country</u>	<u>Trademark</u>	<u>Application or Registration No.</u>	<u>Filing Date</u>	<u>Registration Date</u>	<u>Assignees</u>
Interpace Diagnostics, LLC	US	New Molecule Logo	5067909	3/17/16	10/25/16	N/A
Interpace Diagnostics, LLC	US	PancraGEN	4796668	8/19/14	8/18/15	SWK Funding LLC, as Agent  Redpath Equity Holder Representative
Interpace Diagnostics, LLC	US	PANCRAMIR	86/357914	8/5/14	N/A	SWK Funding LLC, as Agent
Interpace Diagnostics, LLC	US	PANDNA	87/178397	9/21/16	N/A	N/A
Interpace Diagnostics, LLC	US	POWER IN PERFORMANCE	4729240	6/1/14	4/28/15	SWK Funding LLC, as Agent  Redpath Equity Holder Representative
Interpace Diagnostics, LLC	US	ThyGenX	4729279	8/13/14	4/28/15	SWK Funding LLC, as Agent  Redpath Equity Holder Representative
Interpace Diagnostics, LLC	US	THYRAMIR	4882519	8/19/14	1/5/16	SWK Funding LLC, as Agent  Redpath Equity Holder Representative



**Exhibit B  
Patents**

**U.S. Cases:**

<b>Owner</b>	<b>App. No. Patent No.</b>	<b>Filing Date Issue Date</b>	<b>Title</b>	<b>Country</b>
Interpace Diagnostics	60/826,173 NA	09/19/2006 NA	MicroRNAs Differentially Expressed in Pancreatic Disease and Uses Thereof	US
Interpace Diagnostics	11/857,948 NA	9/19/2007 NA	MicroRNAs Differentially Expressed in Pancreatic Disease and Uses Thereof	US
Interpace Diagnostics	61/414,778 NA	11/17/2010 NA	MiRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms	US
Interpace Diagnostics	13/299,226 NA	11/17/2011 NA	MiRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms	US
Interpace Diagnostics	61/534,332 NA	09/13/2011 NA	Methods and Compositions Involving miR-135B for Distinguishing Pancreatic Cancer from Benign Pancreatic Disease	US
Interpace Diagnostics	61/536,486 NA	09/19/2011 NA	Methods and Compositions Involving miR-135B for Distinguishing Pancreatic Cancer from Benign Pancreatic Disease	US
Interpace Diagnostics	13/615,066 9,644,241	9/13/2012 5/9/2017	Methods and Compositions Involving miR-135B for Distinguishing Pancreatic Cancer from Benign Pancreatic Disease	US
Interpace Diagnostics	15/491,399 NA	4/19/2017 NA	Methods and Compositions Involving miR-135B for Distinguishing Pancreatic Cancer from Benign Pancreatic Disease	US
Interpace Diagnostics	61/552,451 NA	10/27/2011 NA	miRNAs as Diagnostic Biomarkers to Distinguish Benign from Malignant Thyroid Tumors	US
Interpace Diagnostics	61/552,762 NA	10/27/2011 NA	miRNAs as Diagnostic Biomarkers to Distinguish Benign from Malignant Thyroid Tumors	US
Interpace Diagnostics	13/662,450 NA	10/27/2012 NA	miRNAs as Diagnostic Biomarkers to Distinguish Benign from Malignant Thyroid Tumors	US
Interpace Diagnostics	61/709,411 NA	10/04/2012 NA	Diagnostic mirnas for Differential Diagnosis of Incidental Pancreatic	US

Owner	App. No. Patent No.	Filing Date Issue Date	Title	Country
			Cystic Lesions	
Interpace Diagnostics	61/716,396 NA	10/19/2012 NA	Diagnostic mirnas for Differential Diagnosis of Incidental Pancreatic Cystic Lesions	US
Interpace Diagnostics	13/801,737 NA	3/13/2013 NA	Diagnostic mirnas for Differential Diagnosis of Incidental Pancreatic Cystic Lesions	US
PDI, Inc.	13/436,259	3/30/2012	Consolidated Presentation Of Pharmaceutical Information From Multiple Sources	US
JS Genetics Inc.	13/266434	4/28/2010	Molecular Diagnosis of Fragile X Syndrome Associated with FMR1 Gene	US
JS Genetics Inc.	13/266429	4/26/2010	Method of Prenatal Molecular Diagnosis of Down Syndrome and Other Trisomic Disorders	US
Interpace Diagnostics Group, Inc.	62/267,619 NA	12/15/2015	Methods for Treating Barrett's Metaplasia and Esophageal Adenocarcinoma	US
Interpace Diagnostics Group, Inc.	15/378,370 NA	12/14/2016	Methods for Treating Barrett's Metaplasia and Esophageal Adenocarcinoma	US

**Foreign Cases:**

Owner	App. No. Patent No.	Filing Date Issue Date	Title	Country
Interpace Diagnostics	PCT/US07/78936 NA	09/19/2007 NA	MicroRNAs Differentially Expressed in Pancreatic Disease and Uses Thereof	PCT
Interpace Diagnostics	2007299828 2007299828 B1	9/19/2007 NA	MicroRNAs Differentially Expressed in Pancreatic Disease and Uses Thereof	AU
Interpace Diagnostics	2,664,383 NA	9/19/2007 NA	MicroRNAs Differentially Expressed in Pancreatic Disease and Uses Thereof	CA
Interpace Diagnostics	12159733 EP 2487240B1	9/19/2007 NA	MicroRNAs Differentially Expressed in Pancreatic Disease and Uses Thereof	EU
Interpace Diagnostics	2009-529373 5520605	9/19/2007 4/11/2014	MicroRNAs Differentially Expressed in Pancreatic Disease and Uses Thereof	JP
Interpace Diagnostics	PCT/US11/61237 NA	11/17/2011 NA	MiRNAs as Biomarkers for Distinguishing Benign from	PCT

Owner	App. No. Patent No.	Filing Date Issue Date	Title	Country
			Malignant Thyroid Neoplasms	
Interpace Diagnostics	2011329772 NA	11/17/2011 NA	MiRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms	AU
Interpace Diagnostics	1120130122650 NA	11/17/2011 NA	MiRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms	BR
Interpace Diagnostics	2817882 NA	11/17/2011 NA	MiRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms	CA
Interpace Diagnostics	14150739.2 EP 2772550B1	11/17/2011 NA	MiRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms	EU
Interpace Diagnostics	226356 NA	11/17/2011 NA	MiRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms	IL
Interpace Diagnostics	2013540026 NA	11/17/2011 NA	MiRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms	JP
Interpace Diagnostics	PCT/US2012/062330 NA	10/27/2012 NA	miRNAs as Diagnostic Biomarkers to Distinguish Benign from Malignant Thyroid Tumors	PCT
Interpace Diagnostics	12787991.4 NA	10/27/2012 NA	miRNAs as Diagnostic Biomarkers to Distinguish Benign from Malignant Thyroid Tumors	EU
Interpace Diagnostics	PCT/US2013/030990 NA	3/13/2013 NA	Diagnostic mirnas for Differential Diagnosis of Incidental Pancreatic Cystic Lesions	PCT
PDI, Inc.	PCT/US2013/034670	3/29/2013	Consolidated Presentation Of Pharmaceutical Information From Multiple Sources	PCT

### Co-owned Patent Applications

Owner	App. No. Patent No.	Filing Date Issue Date	Title	Country
Interpace Diagnostics & Brigham Women's Hospital	13/801,737 NA	3/13/2013 NA	Diagnostic Mirnas For Differential Diagnosis Of Incidental Pancreatic Cystic Lesions	US
Interpace Diagnostics	PCT/US2013/030990 NA	3/13/2013 NA	Diagnostic Mirnas For Differential Diagnosis Of	PCT

& Brigham Women's Hospital			Incidental Pancreatic Cystic Lesions	
----------------------------------	--	--	---	--

**INTERPACE DIAGNOSTICS CORPORATION Patents (Formerly Redpath Patents)**

<u>Pat.No/App. No.</u>	<u>Country</u>	<u>Status</u>	<u>Title</u>	<u>Filing Date</u>	<u>Issue Date</u>	<u>Assignee</u>
2584989	CA	Abandoned	MOLECULAR ANALYSIS OF CELLULAR FLUID AND LIQUID CYTOLOGY SPECIMENS FOR CLINICAL DIAGNOSIS, CHARACTERIZATION, AND INTEGRATION WITH MICROSCOPIC PATHOLOGY EVALUATION	10/24/2005		Interpace Diagnostics Corporation
2585025	CA	Abandoned	DYNAMIC GENOMIC DELETION EXPANSION AND FORMULATION OF MOLECULAR MARKER PANELS FOR INTEGRATED MOLECULAR PATHOLOGY DIAGNOSIS AND CHARACTERIZATION OF TISSUE, CELLULAR FLUID, AND PURE FLUID SPECIMENS	10/24/2005		Interpace Diagnostics Corporation
2584723	CA	Abandoned	ENHANCED AMPLIFIABILITY OF MINUTE FIXATIVE-TREATED TISSUE SAMPLES, MINUTE STAINED CYTOLOGY SAMPLES, AND OTHER MINUTE SOURCES OF DNA	10/24/2005		Interpace Diagnostics Corporation
05818189.2	EP	Abandoned	MOLECULAR ANALYSIS OF CELLULAR FLUID AND LIQUID CYTOLOGY SPECIMENS FOR CLINICAL DIAGNOSIS, CHARACTERIZATION, AND INTEGRATION WITH MICROSCOPIC PATHOLOGY EVALUATION	10/24/2005		Interpace Diagnostics Corporation

<u>Pat.No/App. No.</u>	<u>Country</u>	<u>Status</u>	<u>Title</u>	<u>Filing Date</u>	<u>Issue Date</u>	<u>Assignee</u>
05818314.6	EP	Abandoned	DYNAMIC GENOMIC DELETION EXPANSION AND FORMULATION OF MOLECULAR MARKER PANELS FOR INTEGRATED MOLECULAR PATHOLOGY DIAGNOSIS AND CHARACTERIZATION OF TISSUE, CELLULAR FLUID, AND PURE FLUID SPECIMENS	10/24/2005		Interpace Diagnostics Corporation
05817148.9	EP	Abandoned	ENHANCED AMPLIFIABILITY OF MINUTE FIXATIVE-TREATED TISSUE. SAMPLES, MINUTE STAINED CYTOLOGY SAMPLES, AND OTHER MINUTE SOURCES OF DNA	10/24/2005		Interpace Diagnostics Corporation
60/620926	US	Expired	TOPOGRAPHIC GENOTYPING FOR DEFINING THE DIAGNOSIS, MALIGNANT POTENTIAL, AND BIOLOGICAL BEHAVIOR OF PANCREATIC CYSTS AND RELATED CONDITIONS	10/22/2004		Interpace Diagnostics Corporation
11/255978	US	Abandoned	TOPOGRAPHIC GENOTYPING FOR DETERMINING THE DIAGNOSIS, MALIGNANT POTENTIAL, AND BIOLOGIC BEHAVIOR OF PANCREATIC CYSTS AND RELATED CONDITIONS	10/24/2005		Interpace Diagnostics Corporation
60/631240	US	Expired	TOPOGRAPHIC GENOTYPING FOR DETERMINING THE DIAGNOSIS, MALIGNANT POTENTIAL, AND BIOLOGIC BEHAVIOR OF PANCREATIC CYSTS AND RELATED CONDITIONS	11/29/2004		Interpace Diagnostics Corporation
11/256150	US	Abandoned	MOLECULAR ANALYSIS OF CELLULAR FLUID AND LIQUID CYTOLOGY SPECIMENS FOR CLINICAL DIAGNOSIS, CHARACTERIZATION,	10/24/2005		Interpace Diagnostics Corporation

<u>Pat.No/App. No.</u>	<u>Country</u>	<u>Status</u>	<u>Title</u>	<u>Filing Date</u>	<u>Issue Date</u>	<u>Assignee</u>
			AND INTEGRATION WITH MICROSCOPIC PATHOLOGY EVALUATION			
60/644568	US	Expired	TOPOGRAPHIC GENOTYPING FOR DETERMINING THE DIAGNOSIS, MALIGNANT POTENTIAL, AND BIOLOGIC BEHAVIOR OF PANCREATIC CYSTS AND RELATED CONDITIONS	01/19/2005		Interpace Diagnostics Corporation
11/256152	US	Abandoned	DYNAMIC GENOMIC DELETION EXPANSION AND FORMULATION OF MOLECULAR MARKER PANELS FOR INTEGRATED MOLECULAR PATHOLOGY DIAGNOSIS AND CHARACTERIZATION OF TISSUE, CELLULAR FLUID, AND PURE FLUID SPECIMENS	10/24/2005		Interpace Diagnostics Corporation
60/679968	US	Expired	MOLECULAR ANALYSIS OF CELLULAR FLUIDS SPECIMENS FOR CLINICAL DIAGNOSIS, CHARACTERIZATION, AND INTEGRATION WITH MICROSCOPIC PATHOLOGY EVALUATION	05/12/2005		Interpace Diagnostics Corporation
11/255980	US	Abandoned	ENHANCED AMPLIFIABILITY OF MINUTE FIXATIVE-TREATED TISSUE SAMPLES, MINUTE STAINED CYTOLOGY SAMPLES, AND OTHER MINUTE SOURCES OF DNA	10/24/2005		Interpace Diagnostics Corporation
60/679969	US	Expired	DYNAMIC GENOMIC DELETION EXPANSION: A PREDICTOR OF CANCER BIOLOGICAL AGGRESSIVENESS	05/12/2005		Interpace Diagnostics Corporation
14/305,727	US	Pending	TOPOGRAPHIC GENOTYPING FOR DETERMINING THE DIAGNOSIS, MALIGNANT POTENTIAL, AND	6/16/2014		Interpace Diagnostics Corporation

<u>Pat.No/App. No.</u>	<u>Country</u>	<u>Status</u>	<u>Title</u>	<u>Filing Date</u>	<u>Issue Date</u>	<u>Assignee</u>
			BIOLOGIC BEHAVIOR OF PANCREATIC CYSTS AND RELATED CONDITIONS			
US2005/038315	PCT	Expired	MOLECULAR ANALYSIS OF CELLULAR FLUID AND LIQUID CYTOLOGY SPECIMENS FOR CLINICAL DIAGNOSIS, CHARACTERIZATION, AND INTEGRATION WITH MICROSCOPIC PATHOLOGY EVALUATION	10/24/2005		Interpace Diagnostics Corporation
US2005/038313	PCT	Expired	DYNAMIC GENOMIC DELETION EXPANSION AND FORMULATION OF MOLECULAR MARKER PANELS FOR INTEGRATED MOLECULAR PATHOLOGY DIAGNOSIS AND CHARACTERIZATION OF TISSUE, CELLULAR FLUID, AND PURE FLUID SPECIMENS	10/24/2005		Interpace Diagnostics Corporation
US2005/038311	PCT	Expired	ENHANCED AMPLIFIABILITY OF MINUTE FIXATIVE-TREATED TISSUE SAMPLES, MINUTE STAINED CYTOLOGY SAMPLES, AND OTHER MINUTE SOURCES OF DNA	10/24/2005		Interpace Diagnostics Corporation
US2005/038312	PCT	Expired	TOPOGRAPHIC GENOTYPING FOR DETERMINING THE DIAGNOSIS, MALIGNANT POTENTIAL, AND BIOLOGIC BEHAVIOR OF PANCREATIC CYSTS AND RELATED CONDITIONS	10/24/2005		Interpace Diagnostics Corporation
2198774	CA	Abandoned	TOPOGRAPHIC GENOTYPING	09/22/1995		Interpace Diagnostics Corporation
95935153.7	EP	Abandoned	TOPOGRAPHIC GENOTYPING	09/22/1995		Interpace Diagnostics Corporation
8-511138	JP	Abandoned	TOPOGRAPHIC GENOTYPING	09/22/1995		Interpace Diagnostics Corporation
6,340,563 (08/667493)	US	Granted	TOPOGRAPHIC GENOTYPING	06/24/1996	01/22/2002	Interpace Diagnostics Corporation
7,014,999 (10/008278)	US	Granted	TOPOGRAPHIC GENOTYPING	11/05/2001	03/21/2006	Interpace Diagnostics Corporation

<u>Pat.No/App. No.</u>	<u>Country</u>	<u>Status</u>	<u>Title</u>	<u>Filing Date</u>	<u>Issue Date</u>	<u>Assignee</u>
11/289624	US	Abandoned	TOPOGRAPHIC GENOTYPING	11/30/2005		Interpace Diagnostics Corporation
08/311553	US	Abandoned	TOPOGRAPHIC GENOTYPING	09/23/1994		Interpace Diagnostics Corporation
US95/12372	PCT	Expired	TOPOGRAPHIC GENOTYPING	09/22/1995		Interpace Diagnostics Corporation
61/240919	US	Abandoned	GENERATION OF A COMPREHENSIVE PATHOLOGY REPORT BASED ON MOLECULAR AND GENETIC ANALYSIS	09/09/2009		Interpace Diagnostics Corporation
61/294355	US	Abandoned	METHODS OF COMPARATIVE MUTATIONAL PROFILING	01/12/2010		Interpace Diagnostics Corporation
61/429908	US	Expired	METHODS OF COMPARATIVE MUTATIONAL PROFILING	01/05/2011		Interpace Diagnostics Corporation
61/292561	US	Abandoned	METHODS OF IDENTIFYING BLOOD AND BLOOD-DERIVED DNA CONTENT IN CYST	01/06/2010		Interpace Diagnostics Corporation
61/429900	US	Expired	METHODS OF IDENTIFYING BLOOD AND BLOOD-DERIVED DNA CONTENT IN CYST	01/05/2011		Interpace Diagnostics Corporation
61/297136	US	Abandoned	METHOD OF GENERATING A PATHOLOGY REPORT FOR COMPARATIVE MUTATIONAL PROFILING	01/21/2010		Interpace Diagnostics Corporation
61/425109	US	Expired	MOLECULAR DISCRIMINATION BETWEEN SPORADIC VERSUS TOXIN-ASSOCIATED CANCER FORMATION	12/20/2010		Interpace Diagnostics Corporation
13/331966	US	Abandoned	METHODS OF DIFFERENTIATING BETWEEN NON-GENOTOXIN AND GENOTOXIN-ASSOCIATED TUMORS	12/20/2011		Interpace Diagnostics Corporation
61/443014	US	Expired	METHODS OF DIFFERENTIATING BETWEEN NON-GENOTOXIN VERSUS GENOTOXIN-ASSOCIATED TUMORS	02/15/2011		Interpace Diagnostics Corporation
61/549684	US	Expired	METHODS OF GENOTYPING DNA FROM RESIDUAL SUPERNATANT FLUID FROM BIOLOGICAL SPECIMENS	10/20/2011		Interpace Diagnostics Corporation



<u>Pat.No/App. No.</u>	<u>Country</u>	<u>Status</u>	<u>Title</u>	<u>Filing Date</u>	<u>Issue Date</u>	<u>Assignee</u>
61/565879	US	Expired	METHODS OF IDENTIFYING DYSPLASIA IN A SUBJECT	12/01/2011		Interpace Diagnostics Corporation
13/692727	US	Pending	METHODS FOR TREATING BARRETT'S METAPLASIA AND ESOPHAGEAL ADENOCARCINOMA	12/03/2012		Interpace Diagnostics Corporation
13/954247	US	Pending	METHODS FOR TREATING BARRETT'S METAPLASIA AND ESOPHAGEAL ADENOCARCINOMA	07/30/2013		Interpace Diagnostics Corporation
US 14/46702	PCT	Pending	METHODS FOR TREATING BARRETT'S METAPLASIA AND ESOPHAGEAL ADENOCARCINOMA	07/15/2014		Interpace Diagnostics Corporation
61/612061	US	Expired	METHODS OF GENOTYPING DNA FROM RESIDUAL RADIOCONTRAST AGENT	03/16/2012		Interpace Diagnostics Corporation
61/640527	US	Expired	METHODS FOR DIAGNOSING LOW AND HIGH GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS	04/30/2012		Interpace Diagnostics Corporation
61/661256	US	Expired	METHODS FOR DIAGNOSING LOW AND HIGH GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS	06/18/2012		Interpace Diagnostics Corporation
61/731725	US	Expired	METHODS FOR MEASURING CARCINOEMBRYONIC ANTIGEN	11/30/2012		Interpace Diagnostics Corporation
9,341,638	US	Issued	METHODS FOR MEASURING CARCINOEMBRYONIC ANTIGEN	11/27/2013	5/17/2016	Interpace Diagnostics Corporation
15/147,960	US	Pending	METHODS FOR MEASURING CARCINOEMBRYONIC ANTIGEN	5/6/2016		Interpace Diagnostics Corporation
61/824623	US	Expired	METHODS FOR MEASURING CARCINOEMBRYONIC ANTIGEN	05/17/2013		Interpace Diagnostics Corporation
61/840963	US	Expired	METHODS FOR MEASURING CARCINOEMBRYONIC ANTIGEN	06/28/2013		Interpace Diagnostics Corporation